Development of hydrogen sulfide-based therapeutics for cardiovascular disease.
The physiological role of the gaseous signaling molecule hydrogen sulfide (H(2)S) was first realized in the mid-1990s with the work of Abe and Kimura. Since then, it has become evident that this endogenous gas is extremely important in the homeostasis of the cardiovascular system and the pathogenesis of cardiovascular disease. Several biotechnology companies have developed and are developing H(2)S-based therapeutic compounds, and there are ongoing clinical trials investigating the therapeutic potential of H(2)S. Several organic and chemical compounds that are known H(2)S donors have the potential to be developed into effective H(2)S-based therapeutic agents. This review will provide a historical and current perspective on the role(s) of H(2)S in the cardiovascular system and the current state of development and future outlook of H(2)S-based therapies for cardiovascular disease.
Predmore
Benjamin L
BL
Department of Surgery, Division of Cardiothoracic Surgery, Carlyle Fraser Heart Center, Emory University School of Medicine, 550 Peachtree Street, NE, Atlanta, GA 30308, USA.
Lefer
David J
DJ
D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D006862:Hydrogen Sulfide / Q000378:metabolism / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D057170:Translational Research, Biomedical
D002317:Cardiovascular Agents; D006862:Hydrogen Sulfide